北京德立英捷医药科技

Beijing Deli Yingjie Pharmaceutical Technology Co., Ltd. is a Chinese biopharmaceutical company founded in 2020, operating as a wholly-owned subsidiary of Beijing Deli Furui Pharmaceutical Technology. The company specializes in the research, development, and industrialization of innovative drug delivery systems, with a particular focus on self-emulsifying drug delivery systems (SEDDS) and polymeric micelles to improve the solubility and bioavailability of poorly soluble drugs. Its lead program, a self-emulsifying docetaxel injection concentrate (多西他赛注射用浓溶液（自乳化型）), is developed for the treatment of advanced breast cancer and non-small cell lung cancer and has reached the NDA submission stage in China. Additionally, the company is advancing other formulation-improved candidates, such as posaconazole solid dispersions and nimodipine formulations, targeting oncology, infectious diseases, and cardiovascular conditions.